PINTaD Meetings
When We Meet
PINTaD meets on the last Wednesday of each month, 11:00–12:00 ET, online. Members receive a calendar invitation and joining details by email.
Meeting Format
Each session features a presentation on a single topic by a member or guest speaker, followed by an open discussion and Q&A. Past sessions have covered topics like response criteria in lymphoma, focused ultrasound blood-brain barrier disruption, statistical considerations for validating imaging biomarkers, FDA and ODAC lessons on BICR, tumor growth modeling, and quality management of PET-CT.
The presentation opens the question, but discussion is always our objective.
Upcoming Topics
December 2026
TBD
25 November 2026
Long AFOV PET Scanners Harmonization
Propose a Topic
PINTaD Presentation Guidelines
Scope
Presentations must emphasize science and relevant research directly related to the meeting’s focus areas.
Presentations must align with the PINTaD Mission Statement and Purpose and cannot be for marketing purposes.
Mission: To provide a forum to evaluate, discuss, and recommend methods and strategies for imaging in clinical trials, for the sake of all stakeholders.
Purpose: To give the various stakeholders in imaging clinical trials a voice with which to influence and advance the field, and to further its acceptance by industry and regulatory bodies.
Duration and Format
Meeting timeslot is typically one hour:
Housekeeping and introduction ~10 minutes
Presentation ~35 minutes
Questions and Wrap-Up ~15 minutes
Presentations should be concise, aligning with allotted time limits and allowing time for questions.
Company Introduction
Company introductions are limited to one introductory slide (max 2 minutes) summarizing the company’s scientific expertise, mission, and areas of focus.
Prohibited Content
Advertising or promotional content unrelated to science or research.
Any material that may overshadow the scientific focus of the session.
Meetings Archive
Slides, video recordings, and meeting minutes are available in the meetings archive.